Effect of inhibition or deletion of neutral endopeptidase on neuropathic endpoints in high fat fed/low dose streptozotocin-treated mice

Journal of Neuropathology and Experimental Neurology

Volumn 75, Issue 11, 2016, Pages 1072-1080

  Yorek, Matthew S ^a   Obrosov, Alexander ^b   Lu, Bao ^c   Gerard, Craig ^b   Kardon, Randy H ^a,b,d   Yorek, Mark A ^a,b,d  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d VA Center of Excellence for Prevention and Treatment of Visual Loss   (United States)

Author keywords

Candoxatril; Corneal nerves; Diabetes; Diabetic neuropathy; Neprilysin; Neutral endopeptidase

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CANDOXATRIL; GLUCOSE; MEMBRANE METALLOENDOPEPTIDASE; STREPTOZOCIN; TUBULIN; TUBULIN III; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE DELETION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LIPID DIET; MALE; MOUSE; NOCICEPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORY NERVE CONDUCTION VELOCITY; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY;

EID: 84996487053     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1093/jnen/nlw083     Document Type: Article

References (68)

1. Kim H, Kim JJ, Yoon YS. Emerging therapy for diabetic neuropathy: Cell therapy targeting vessels and nerves. Endocr Metab Immune Disord Drug Targets 2012; 12: 168-78
2. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 2008; 9: 301-14
3. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits. Am J Physiol 1991; 261: E1-8
4. Nukada H, Dyck PJ. Microsphere embolization of nerve capillaries and fiber degeneration. Am J Pathol 1984; 115: 275-87
5. Cameron NE, Cotter MA, Dines KC, et al. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myoinositol mechanism. Diabetologia 1994; 37: 651-63
6. Cameron NE, Cotter MA, Archibald V, et al. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994; 37: 449-59
7. Cotter MA, Dines KC, Cameron NE. Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocindiabetic rats by the prostacyclin analogue iloprost. Naunyn Schmiedebergs Archives Pharm 1993; 347: 534-40
8. Cameron NE, Cotter MA, Dines KC, et al. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992; 35: 946-50
9. Sima AA. Pathological mechanisms involved in diabetic neuropathy: Can we slow the process? Curr Opin Invest Drugs 2006; 7: 324-37
10. Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 2006; 22: 257-73
11. Pu Q, Schiffrin EL. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats. Am J Hypertens 2001; 14: 1067-72
12. Ebihara F, Di Marco GS, Juliano MA, et al. Neutral endopeptidase expression in mesangial cells. J Renin-Angiotensin-Aldosterone Syst 2003; 4: 228-33
13. Vatter H, Schilling L, Schmiedek P, et al. Evidence for functional endothelin-converting enzyme activity in isolated rat basilar artery: Effect of inhibitors. J Cardiovasc Pharmaco 1998; 31: S64-7
14. Muangman P, Spenny ML, Tamura RN, et al. Fatty acids and glucose increase neutral endopeptidase activity in human microvascular endothelial cells. Shock 2003; 19: 508-12
15. Edwards RM, Pullen M, Nambi P. Distribution of neutral endopeptidase activity along the rat and rabbit nephron. Pharmacology 1999; 59: 45-50
16. Gonzalez W, Soleilhac JM, Fournie-Zaluski MC, et al. Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels. Eur J Pharmacol 1998; 345: 323-31
17. Matsas R, Kenny AJ, Turner AJ. An immunohistochemical study of endopeptidase-24.11 ("enkephalinase") in the pig nervous system. Neuroscience 1986; 18: 991-1012
18. Kioussi C, Mamalaki A, Jessen K, et al. Expression of endopeptidase- 24.11 (common acute lymphoblastic leukaemia antigen CD10) in the sciatic nerve of the adult rat after lesion and during regeneration. Eur J Neurosci 1995; 7: 951-61
19. Coppey L Lu B, Gerard C, et al. Effect of inhibition of angiotensinconverting enzyme and/or neutral endopeptidase on neuropathy in highfat- fed C57Bl/6J mice. J Obes 2012; 2012: 326806
20. Oltman CL, Davidson EP, Coppey LJ, et al. Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats. Eur J Pharmacol 2011; 15: 556-62
21. Oltman CL, Davidson EP, Coppey LJ, et al. Treatment of Zucker fatty rats with AVE7688 improves vascular and neural dysfunction. Diabetes Obes Metab 2009; 11: 223-33
22. Davidson EP, Kleinschmidt TL, Oltman CL, et al. Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: Effect on vascular and neural disease. Diabetes 2007; 56: 355-62
23. Davidson EP, Coppey LJ, Holmes A, et al. Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats. Eur J Pharmacol 2012; 677: 180-7
24. Davidson EP, Coppey LJ, Holmes A. Effect of treatment of high fat fed/ low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.2011. Eur J Pharmcol 2011; 668: 497-506
25. Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007; 56: 2148-54
26. Rosa E, Cha J, Bain JR, et al. Calcitonin gene-related peptide regulation of glial cell-line derived neurotrophic factor in differentiated rat myotubes. J Neurosci Res 2015; 93: 514-20
27. Fu C, Yin Z, Yu D, et al. Substance P and calcitonin gene-related peptide expression in dorsal root ganglia in sciatic nerve injury rats. Neural Regen Res 2013; 8: 3124-30
28. Hashhikawa-Hobara N, Hashikawa N, Zamami Y, et al. The mechanism of calcitonin gene-related peptide-containing nerve innervation. J Pharmacol Sci 2012; 119: 117-21
29. Cortina MS, He J, Li N, et al. Recovery of corneal sensitivity, calcitonin gene-related peptide-positive nerves, and increased wound healing induced by pigment epithelial-derived factor plus docosahexaenoic acid after experimental surgery. Arch Ophthalmol 2012; 130: 76-83
30. Toth CC, Willis D, Twiss JL, et al. Locally synthesized calcitonin generelated peptide has a critical role in peripheral nerve regeneration. J Neuropathol Exp Neurol 2009; 68: 326-37
31. Lu B, Gerard NP, Kolakowski LF. Jr., et al. Neutral endopeptidase modulation of septic shock. J Exp Med 1995; 181: 2271-5
32. Ayoub S, Melzig MF. Induction of neutral endopeptidase (NEP) activity of SK-N-SH cells by natural compounds from green tea. J Pharm Pharmacol 2005; 58: 495-501
33. Davidson E, Coppey L, Lu B, et al. The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Exp Diabetes Res 2009; 2009: 431980
34. Coppey L, Davidson E, Lu B, et al. Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- And diabetes-induced neuropathy in C57Bl/6J mice. Neuropharmacology 2011; 60: 259-66
35. Yorek MS, Obrosov A, Shevalye H, et al. Effect of glycemic control on corneal nerves and peripheral neuropathy in streptozotocin-induced diabetic C57Bl/6J mice. J Peripher Nerv Syst 2014; 19: 205-17
36. Malik RA, Kallinikos P, Abbott CA, et al. Corneal confocal microscopy: A non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 2003; 46: 683-8
37. Tavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med 2011; 28: 1261-7
38. Yorek MS, Obrosov A, Shevalye H, et al. Effect of diet-induced obesity or type 1 or type 2 diabetes on corneal nerves and peripheral neuropathy in C57Bl/6J mice. J Peripher Nerv Syst 2015; 20: 24-31
39. Shevalye H, Yorek MS, Coppey LJ, et al. Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. J Neurophysiol 2015; 114: 199-208
40. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: An open-source platform for biological-image analysis. Nat Methods 2012; 9: 676-82
41. Stavniichuk R, Shevalye H, Lupachyk S, et al. Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2014; 30: 669-78
42. Azmi S, Ferdousi M, Petropoulos IN, et al. Corneal confocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type 2 diabetes. Diabetes Care 2015; 38: 1502-8
43. Asghar O, Petropoulos IN, Alam U, et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care 2014; 37: 2643-6
44. Tavakoli M, Petropoulos IN, Malik RA. Assessing corneal nerve structure and function in diabetic neuropathy. Clin Exp Optom 2012; 95: 338-47
45. Edwards K, Pritchard N, Vagenas D, et al. Utility of corneal confocal microscopy for assessing mild diabetic neuropathy: Baseline findings of the LANDMark study. Clin Exp Optom 2012; 54
46. Davidson EP, Coppey LJ, Kardon RH, et al. Differences and similarities in development of corneal nerve damage and peripheral neuropathy in diet-induced obesity and type 2 diabetic rats. Invest Ophthalmol Vis Sci 2014; 55: 1222-30
47. Pritchard N, Dehghani C, Edwards K, et al. Utility of assessing nerve morphology in central cornea versus whorl area for diagnosing diabetic peripheral neuropathy. Cornea 2015; 34: 756-61
48. Petropoulos IN, Ferdousi M, Marshall A, et al. The inferior whorl for detecting diabetic peripheral neuropathy using corneal confocal microscopy. Invest Ophthalmol Vis Sci 2015; 56: 2498-504
49. Davidson EP, Coppey LJ, Yorek MA. Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic ras: Improvement with ilepatril treatment. Invest Ophthalmol Vis Sci 2012; 53: 8067-74
50. Yorek MA. The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy. Curr Drug Targets 2008; 9: 77-84
51. Prenner SB, Shah SJ, Yancy CW. Role of angiotensin receptorneprilysin inhibition in heart failure. Curr Atheroscler Rep 2016; 18: 48
52. Bavishi C, Messerli FH, Kadosh B, et al. Role of neprilysin inhibitor combinations in hypertension: Insights from hypertension and heart failure trials. Eur Heart J 2015; 36: 1967-73
53. von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 2014; 144: 41-9
54. Judge P, Haynes R, Landray MJ, et al. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant 2015; 30: 738-43
55. Spenny ML, Muangman P, Sullivan SR, et al. Neutral endopeptidase inhibition in diabetic wound repair. Wound Repair Regen 2002; 10: 295-301
56. Olerud JE, Usui ML, Seckin D, et al. Neutral endopeptidase expression and distribution in human skin and wounds. J Invest Dermatol 1999; 112: 873-81
57. Jiucheng H, Bazan HEP. Neuroanatomy and neurochemistry of mouse cornea. Cornea 2016; 57: 664-74
58. Schlereth T, Breimhorst M, Werner N. Inhibition of neuropeptide degradation suppresses sweating but increases the area of the axon reflex flare. Exp Dermatol 2013; 22: 299-301
59. Kramer HH, He L, Lu B, et al. Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase. Neurobiol Dis 2009; 35: 177-83
60. Kramer HH, Schmidt K, Leis S, et al. Angiotensin converting enzyme has an inhibitory role in CGRP metabolism in human skin. Peptides 2006; 27: 917-20
61. Leal EC, Carvalho E, Tellechea A, et al. Substance P promotes would healing in diabetes modulating inflammation and macrophage phenotype. Am J Pathol 2015; 185: 1638-48
62. Yang Q, Du X, Fang Z, et al. Effect of calcitonin gene-related peptide on the neurogenesis of rat adipose-derived stem cells in vitro. Plos One 2014; 9: E86334
63. Kashihara Y, Sakaguchi M, Kuno M. Axonal transport and distribution of endogenous calcitonin gene-related peptide in rat peripheral nerve. J Neurosci 1989; 9: 3796-802
64. Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep 2015; 15: 25
65. Blesch A, Tuszynski MH. GDNF gene delivery to injured adult CNS motor neurons promotes axonal growth, expression of the trophic neuropeptide CGRP, and cellular protection. J Comp Neurol 2001; 436: 399-410
66. Chen LJ, Zhang FG, Li J, et al. Expression of calcitonin gene-related peptide in anterior and posterior horns of the spinal cord after brachial plexus injury. J Clin Neurosci 2010; 17: 87-91
67. Zhang L, Lv X, Tong X, et al. Study on molecular mechanism for improving neural regeneration after repair of sciatic nerve defect in rat by acellular nerve allograft. Synapse 2012; 66: 52-60
68. Li XQ, Verge VM, Johnston JM, et al. CGRP peptide and regenerating sensory axons. J Neuropathol Exp Neurol 2004; 63: 1092-103